한울 바이오
한울 바이오's KOBDi Score is 25.42 as of Sep 2026, up 2.56 points since Apr 2025; it rose in 3 of the 12 monthly updates and never fell. As of Sep 2026 it is ahead of about 52% of companies in its industry, against 52% in Aug 2026 and 58% in Apr 2025. Its strongest position was 58% (May 2025) and its weakest 51% (Aug 2025).
A year earlier, in Aug 2025, its score was 23.02 and it was ahead of about 51% of companies in its industry.
| Sep 2026 | 25.42 | ahead of 52% |
| Aug 2026 | 25.42 | ahead of 52% |
| Jul 2026 | 25.26 | ahead of 53% |
| Jun 2026 | 25.26 | ahead of 53% |
| May 2026 | 25.26 | ahead of 53% |
| Apr 2026 | 25.26 | ahead of 54% |
| Mar 2026 | 25.26 | ahead of 54% |
| Feb 2026 | 25.26 | ahead of 53% |
| Dec 2025 | 25.26 | ahead of 53% |
| Aug 2025 | 23.02 | ahead of 51% |
| Jul 2025 | 22.86 | ahead of 57% |
| May 2025 | 22.86 | ahead of 58% |
| Apr 2025 | 22.86 | ahead of 58% |
Where is 한울 바이오 located?
한울 바이오 is registered at 경상남도 양산시 상북면 석계산단6길, South Korea (postal code 50561).
What industry is 한울 바이오 in?
한울 바이오 belongs to Manufacturing › Refractory Ceramics › Manufacture of irregular refractory ceramic products.
How many employees does 한울 바이오 have?
한울 바이오 has 5–9 employees.
What is 한울 바이오's KOBDi Score?
25.42 as of September 2026, ahead of about 52% of companies in its industry.
Who are 한울 바이오's competitors?
Similar companies include 류성내화공업사, 대흥중자 and 신흥산업사.

